A Long-Term Extension Study for Participants With Treatment-resistant

Clinical Trial Summary

The primary purpose of this study is to assess the long-term safety and tolerability of esketamine nasal spray in combination with a selective serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitor (SSRI/SNRI) in participants who have completed 32 weeks of esketamine nasal spray treatment in Study 54135419TRD3013 (NCT04338321).

See also
Status	Clinical Trial	Phase
Completed	`NCT04469322` - Pharmacogenetic Implementation Trial in Veterans With Treatment Refractory Depression	N/A
Completed	`NCT02919501` - Study of the Efficacy and Safety of Initial Administration of 17 mg Vortioxetine Intravenously With 10 mg/Day Vortioxetine Orally in Patients With Major Depressive Disorder	Phase 2
Completed	`NCT00976560` - Clinical Study to Test a New Drug to Treat Major Depression	Phase 2
Not yet recruiting	`NCT03693105` - The Effects of Stanford Accelerated Intelligent Neuromodulation Therapy on Explicit and Implicit Suicidal Cognition	N/A
Suspended	`NCT02546024` - Predictors of Treatment Response in Late-onset Major Depressive Disorder	N/A
Completed	`NCT02452892` - Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)	N/A
Completed	`NCT01407575` - Buprenorphine for Treatment Resistant Depression	Phase 3
Completed	`NCT01583400` - Enhanced Collaborative Depression Treatment in Primary Care: The RESPECT-D-E Trial	N/A
Completed	`NCT01152996` - Safety and Tolerability of Vortioxetine (LuAA21004) - Open Label Extension Study	Phase 3
Enrolling by invitation	`NCT00762866` - Psychiatric Genotype/Phenotype Project Repository
Completed	`NCT00369343` - Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) Versus Placebo in Peri- and Postmenopausal Women	Phase 3
Completed	`NCT00366652` - Study Evaluating the Effects of DVS SR and Duloxetine on the Pharmacokinetics of Desipramine in Healthy Subjects	Phase 3
Completed	`NCT00384033` - Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) In The Treatment Of Major Depressive Disorder	Phase 3
Completed	`NCT00316160` - Sexual Functioning Study With Antidepressants	Phase 4
Completed	`NCT00149643` - Effectiveness of Fluoxetine in Young People for the Treatment of Major Depression and Marijuana Dependence	Phase 2
Recruiting	`NCT04533529` - A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant and Long-term Safety Extension Treatment With Seltorexant	Phase 3
Recruiting	`NCT04532749` - A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy	Phase 3
Recruiting	`NCT04513912` - A Study of Seltorexant Compared to Quetiapine XR as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy	Phase 3
Recruiting	`NCT04116606` - Antidepressant Trial With P2X7 Antagonist JNJ-54175446	Phase 2
Terminated	`NCT00569062` - A Study of GW856553X For the Treatment of Depression	Phase 2

NCT number	NCT04829318
Study type	Interventional
Source	Janssen-Cilag Ltd.
Contact	Study Contact
Phone	844-434-4210
Email	[email protected]
Status	Not yet recruiting
Phase	Phase 4
Start date	April 26, 2021
Completion date	August 5, 2024

A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment — ESCAPE-LTE

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms